Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Omega-3 Fatty Acids for Major Depressive Disorder During Pregnancy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00618865
Recruitment Status : Completed
First Posted : February 20, 2008
Last Update Posted : February 20, 2008
Sponsor:
Information provided by:
National Science Council, Taiwan

Brief Summary:
Whether high-dose omega-3 fatty acids supplement would be an effective treatment in patients with major depressive disorder during pregnancy and breast-feeding.

Condition or disease Intervention/treatment Phase
Depressive Disorder Dietary Supplement: Omega-3 fatty acids Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Omega-3 Polyunsaturated Fatty Acids in Women With Major Depressive Disorders During Pregnancy
Study Start Date : June 2004
Actual Primary Completion Date : June 2004
Actual Study Completion Date : June 2004

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 1
omega-3 fatty acid with 2.2 g of eicosapentanoic acid (EPA) and 1.2 g of docosahexanoic acid (DHA)
Dietary Supplement: Omega-3 fatty acids
Placebo Comparator: 2
Placebo (olive oil ethyl esters)
Dietary Supplement: Omega-3 fatty acids




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eligible participants were pregnant women, aged 18 to 40 years, with major depressive disorder onset between their 16th week (second trimester) and 32nd week (third trimester) of gestation at the Department of Obstetrics.

Exclusion Criteria:

  • Subjects were excluded with a DSM-IV diagnosis of bipolar disorders, psychotic disorders, substance abuse or dependence for at least 3 months, or any Axis-II diagnosis of borderline or antisocial personality disorder.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Kuan-Pin Su, China Medical University Hospital
ClinicalTrials.gov Identifier: NCT00618865    
Other Study ID Numbers: NSC 93-2320-B-039-001
First Posted: February 20, 2008    Key Record Dates
Last Update Posted: February 20, 2008
Last Verified: February 2008
Keywords provided by National Science Council, Taiwan:
Omega-3 Fatty Acids
Major Depressive Disorder
Pregnancy
Women during pregnancy and after childbirth are more vulnerable to psychiatric disorders
Pharmacotherapy for depression during pregnancy is a clinical dilemma.
Omega-3 polyunsaturated fatty acids (PUFAs) might be a promising alternative of treatment for pregnant women with depression.
Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Depressive Disorder
Depression
Depressive Disorder, Major
Pathologic Processes
Mood Disorders
Mental Disorders
Behavioral Symptoms